Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with Adjuvant Chemotherapy in HR-Negative Breast Cancer
NCT05978648Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trilaciclib in breast cancer (2 cohorts). Primary endpoint: Occurrence of Grade 3/4 neutropenia at 24 weeks. Started Sep 2023; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05978648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978648.